Clinical Trial Update: Teclistamab-Daratumumab in AL Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of teclistamab and daratumumab for amyloid light-chain (AL) amyloidosis; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Light-chain Amyloidosis

Drugs mentioned

• DARZALEX (daratumumab)
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Suzanne Lentzsch, MD | Conditions: Amyloid Light-chain Amyloidosis | Phase 2 | Status: RECRUITING